When a New York woman’s lung cancer spread to her brain, her son faced a devastating reality: the medicine that might help her was available in China, but not yet approved in the United States.
Rather than give up, he boarded a plane to Shanghai.
He returned carrying 26 boxes of a specialized cancer medication worth approximately $10,000.
What happened next became an extraordinary story of determination, modern cancer treatment, and the growing international race to develop life-saving medicines.
According to an investigation published by KFF Health News on October 20, 2026, the woman was still benefiting from the treatment approximately 19 months after starting it.
Her cancer had remained largely under control, with additional radiation treatments and adjustments to her medication.
But the most surprising detail may be that the drug was already being sold in China years before American patients could obtain it commercially.
And now, that same medication has finally become available in the United States.
A Mother’s Cancer Diagnosis Changed Everything
In late 2023, Debbie Doppelt, a 60-year-old jewelry business owner from New York City, noticed a persistent cough.
What initially appeared to be a relatively ordinary symptom eventually led to a frightening diagnosis.
She had lung cancer.
Debbie had never smoked, but her cancer belonged to a group of lung tumors associated with specific genetic changes.
Her medical team began treatment using established approaches, including chemotherapy, immunotherapy, and surgery.
For a time, these treatments helped control the disease.
Then, in December 2024, doctors discovered that the cancer had spread to her brain.
Scans revealed approximately 10 small brain tumors.
For Debbie and her family, this was a devastating development.
Brain metastases can be particularly challenging because not every cancer medication reaches the brain in sufficient concentrations to control tumors.
Her son, Max Doppelt, began searching for additional treatment options.
What he discovered would eventually take him thousands of miles from home.
The Cancer Drug That Was Available in China but Not America
Max learned about a medication called sunvozertinib.
Developed by Shanghai-based Dizal Pharmaceutical, sunvozertinib is a targeted therapy designed for certain lung cancers carrying a specific genetic mutation.
The mutation is known as an EGFR exon 20 insertion.
Unlike conventional chemotherapy, which affects rapidly dividing cells throughout the body, targeted therapies are designed to interfere with particular molecular mechanisms involved in cancer growth.
Sunvozertinib had already received regulatory approval in China in 2023.
However, when Debbie needed it in early 2025, the drug had not yet been approved by the US Food and Drug Administration.
It was being investigated in clinical trials, but accessing those trials was not straightforward.
Debbie had hoped to participate in a study involving another experimental medication at Memorial Sloan Kettering Cancer Center.
Unfortunately, she was declared ineligible because of a small amount of scarring in her lungs.
Another treatment option, amivantamab, was already approved for certain patients with her mutation, but there were concerns about its side effects and ability to reach cancer in the brain.
The family was running out of acceptable options.
Then a doctor mentioned something unexpected.
The medicine Max was searching for could already be purchased through pharmacies in China.
He Boarded a Plane and Returned With 26 Boxes of Medicine
The family initially obtained a small supply of sunvozertinib through a contact living in China.
After Debbie began taking the medication, Max needed to secure additional supplies.
A few months later, he traveled to Shanghai himself.
He returned to New York carrying 26 boxes of sunvozertinib in his luggage.
The medication cost approximately $10,000.
For Max, the journey was more than a desperate attempt to obtain a drug.
It represented an opportunity to give his mother additional time.
He believed that available clinical data suggested the medication might have activity against the particular cancer mutation driving her disease.
However, bringing prescription medication across international borders can involve significant legal, medical, and quality-control risks.
The family’s experience should not be interpreted as evidence that obtaining unapproved medicines abroad is generally safe or advisable.
In this case, the decision was made under extraordinary circumstances involving advanced cancer and limited treatment options.
19 Months Later, Her Cancer Was Still Largely Under Control
The outcome attracted widespread attention.
By October 2026, Debbie had been taking sunvozertinib for approximately 19 months.
According to the family’s account reported by KFF Health News, her cancer remained mostly controlled.
She had also received several radiation treatments and medication dose adjustments.
Remarkably, Debbie continued working in the diamond business she operates with her husband.
Despite living with advanced cancer, she had missed very little work.
Her story offered an encouraging example of how precision oncology can sometimes help patients whose cancers have stopped responding adequately to earlier treatments.
However, there is an important distinction.
Her cancer was controlled, not declared cured.
Advanced lung cancer can develop resistance to targeted medications over time.
And an individual patient’s unusually durable response cannot establish how long the treatment will work for everyone else.
Nevertheless, her experience highlights the potential value of identifying the specific genetic changes driving a patient’s tumor.
What Is Sunvozertinib, and Why Is It Different?
Sunvozertinib, sold in the United States under the brand name Zegfrovy, belongs to a class of medications known as tyrosine kinase inhibitors.
It targets the epidermal growth factor receptor, or EGFR.
EGFR is a protein involved in regulating cell growth and division.
Under normal circumstances, it helps cells respond to growth signals.
But certain mutations can cause EGFR to remain abnormally active.
When that happens, cells may receive continuous signals encouraging them to multiply.
This can contribute to the growth and spread of cancer.
Not all EGFR mutations are the same.
Some common mutations respond well to established targeted therapies.
Others are more difficult to treat.
The EGFR exon 20 insertion mutation is one of these challenging alterations.
Sunvozertinib was developed to inhibit abnormal EGFR signaling in tumors carrying this particular mutation.
This is why the medication is not a universal treatment for lung cancer.
It is intended for a specific group of patients whose tumors meet defined molecular and clinical criteria.
The Clinical Trial Results: How Effective Is the Drug?
The FDA granted sunvozertinib accelerated approval on July 2, 2025, based on results from a clinical trial known as WU-KONG1B.
The primary analysis evaluated 85 patients with advanced non-small cell lung cancer carrying EGFR exon 20 insertion mutations.
Their cancer had progressed during or after platinum-based chemotherapy.
The results were encouraging.
46% of patients experienced a confirmed reduction in tumor size.
Among the patients whose tumors responded, the median duration of response was approximately 11.1 months.
This means half of the responding patients maintained their response longer than that period, while half experienced a shorter response.
These results are significant for a group of patients with limited treatment options.
However, the numbers must be interpreted carefully.
A 46% response rate does not mean the medication cures 46% of patients.
And a median response duration of 11.1 months does not mean every patient benefits for that length of time.
Some patients may respond for considerably longer, while others may receive little or no benefit.
Because the drug received accelerated approval, additional studies are required to confirm its clinical benefits.
Why Didn’t the United States Have the Drug Earlier?
The difference in availability reflects several factors involved in drug development and regulation.
China approved sunvozertinib in 2023.
The United States granted accelerated approval in July 2025.
However, the drug did not become commercially available to American patients until October 22, 2026.
This created a period during which some patients could potentially access the drug in China but not through ordinary US pharmacy distribution.
Drug approval and commercial availability are separate processes.
Even after a medicine receives regulatory clearance, companies may need to establish manufacturing, distribution, commercial partnerships, and patient access programs.
In September 2026, AstraZeneca completed a licensing agreement with Dizal Pharmaceutical to develop and commercialize sunvozertinib internationally.
The company subsequently announced the drug’s US availability on October 22.
This development means eligible American patients no longer need to travel to China simply because the medicine is unavailable through US commercial channels.
Debbie’s experience occurred during an unusual period when access depended partly on geography and timing.
A Remarkable Shift in Global Cancer Research
For decades, the United States and Europe have played leading roles in developing many of the world’s most influential cancer treatments.
But China’s pharmaceutical research sector has expanded rapidly.
Chinese biotechnology companies are increasingly developing targeted cancer medicines, immune therapies, and other specialized treatments.
Some international pharmaceutical companies have entered partnerships to license drugs discovered or developed in China.
This reflects the increasingly global nature of medical innovation.
Cancer treatments may originate in one country, undergo clinical testing in several others, and eventually reach patients worldwide through international agreements.
However, faster development does not automatically mean that every new treatment is safer or more effective.
Regulatory agencies must evaluate the quality of clinical evidence, manufacturing standards, and the balance of expected benefits against potential risks.
International collaboration can be valuable, but rigorous medical oversight remains essential.
What Are the Potential Side Effects of Sunvozertinib?
Like other cancer treatments, sunvozertinib can cause significant adverse effects.
The FDA prescribing information identifies several important risks, including:
- Interstitial lung disease and pneumonitis
- Diarrhea and other gastrointestinal reactions
- Skin-related adverse reactions
- Eye problems and ocular toxicity
- Potential harm to a developing fetus
Some reactions can be serious and require treatment interruption, dose adjustment, or discontinuation.
This is particularly important for patients with preexisting lung disease.
The medication should be prescribed and monitored by an oncology team familiar with targeted cancer treatments.
It is not suitable for everyone with lung cancer, and patients should never attempt to obtain or use it without appropriate medical supervision.
Why Genetic Testing Is Becoming So Important in Cancer Treatment
One of the most valuable lessons from Debbie’s story is the importance of tumor biomarker testing.
Traditionally, many cancer treatments were selected primarily according to the organ in which a tumor developed.
Modern oncology increasingly considers the specific genetic and molecular characteristics of a tumor.
Two patients with lung cancer may have very different mutations.
As a result, a treatment that works well for one patient may be ineffective for another.
Biomarker testing can identify genetic alterations such as EGFR mutations and help oncologists select appropriate targeted therapies.
For eligible patients, the results may also reveal opportunities to participate in clinical trials.
However, genetic testing does not guarantee that a targeted drug will be available or effective.
Cancer treatment decisions still depend on the disease stage, previous treatment, overall health, and many other factors.
A Son’s Experience Inspired Another Mission
Max Doppelt’s search for his mother’s treatment also changed his professional life.
A computer engineer by training, Max became deeply involved in cancer research and clinical trial information while investigating Debbie’s options.
He eventually developed a technology platform using artificial intelligence to help patients identify potentially suitable cancer trials.
According to the October 2026 KFF Health News report, approximately 300 patients had used the service.
The platform was designed to compare medical information with clinical trial eligibility requirements.
Max’s experience highlighted a problem affecting many patients with advanced cancer.
Potentially useful clinical trials may exist, but finding studies that match a patient’s diagnosis, genetic mutations, treatment history, and location can be extremely difficult.
Technology may help organize that information, although trial eligibility and treatment decisions must still be confirmed by qualified medical professionals.
Does This Mean Patients Should Travel Abroad for Cancer Treatment?
Not necessarily.
Debbie’s story is inspiring, but it also raises serious questions about treatment access and safety.
Cancer medications obtained outside established medical systems may present risks involving product authenticity, storage, quality control, and medical supervision.
A drug approved in another country may not have the same approved indications or monitoring requirements.
Importing prescription medications can also involve legal restrictions.
For patients facing limited treatment options, a safer first step is to discuss clinical trials, expanded access programs, biomarker testing, and available targeted therapies with an oncology specialist.
The circumstances that led Max to travel to China have also changed.
Sunvozertinib is now commercially available in the United States for eligible patients.
Therefore, the story should not be used to encourage readers to purchase cancer medication from foreign pharmacies or unverified online sellers.
The Bigger Lesson: Cancer Treatment Is Becoming More Personalized
Debbie Doppelt’s experience demonstrates how much cancer treatment has changed.
For certain patients, identifying a specific tumor mutation can reveal therapeutic options that would not have been available through a more generalized approach.
Targeted therapies are not miracle cures.
They do not work for everyone, and drug resistance remains a serious challenge.
But they can sometimes provide meaningful disease control, even after previous treatments have stopped working.
For Debbie, sunvozertinib became an important part of managing advanced lung cancer.
For her son, finding that medication became a mission that eventually inspired efforts to help other patients navigate complex treatment options.
And for the broader medical community, the case highlights why international research cooperation and timely access to effective treatments matter.
The Bottom Line
When Debbie Doppelt’s lung cancer spread to her brain, her family faced a frightening shortage of suitable treatment options.
Her son traveled to China and returned with 26 boxes of a targeted cancer medication that was not yet commercially available in the United States.
Approximately 19 months after starting sunvozertinib, Debbie’s cancer remained largely under control with the help of additional treatment.
The drug has since received FDA accelerated approval and become available in the United States under the name Zegfrovy.
Her story is not proof of a universal cancer cure.
It is a powerful example of how identifying the right molecular target, obtaining appropriate treatment, and improving access to medical innovation can sometimes change a patient’s outlook.
Sometimes, the difference between having another treatment option and running out of options comes down to access, timing, and a single genetic mutation.
Medical disclaimer: This article is intended for educational purposes only. Targeted cancer treatments require specialist evaluation, appropriate biomarker testing, and medical supervision. Patients should never change cancer treatment or obtain prescription medicines from unverified sources without consulting their oncology team.
